Hydrogen Sulphide Release via the Angiotensin Converting Enzyme Inhibitor Zofenopril Prevents Intimal Hyperplasia in Human Vein Segments and in a Mouse Model of Carotid Artery Stenosis.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
02 2022
Historique:
received: 16 02 2021
revised: 01 09 2021
accepted: 17 09 2021
pubmed: 18 12 2021
medline: 8 3 2022
entrez: 17 12 2021
Statut: ppublish

Résumé

Hypertension is a major risk factor for intimal hyperplasia (IH) and re-stenosis following vascular and endovascular interventions. Preclinical studies suggest that hydrogen sulphide (H Spontaneously hypertensive male Cx40 deleted mice (Cx40 Compared with control animals (intima/media thickness 2.3 ± 0.33 μm), enalapril reduced IH in Cx40 Zofenopril provides extra beneficial effects compared with non-sulfhydryl ACEi in reducing SMC proliferation and re-stenosis, even in normotensive animals. These findings may hold broad clinical implications for patients suffering from vascular occlusive diseases and hypertension.

Identifiants

pubmed: 34916111
pii: S1078-5884(21)00771-1
doi: 10.1016/j.ejvs.2021.09.032
pii:
doi:

Substances chimiques

Angiotensin-Converting Enzyme Inhibitors 0
zofenopril 290ZY759PI
Captopril 9G64RSX1XD
Hydrogen Sulfide YY9FVM7NSN

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

336-346

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest None.

Auteurs

Diane Macabrey (D)

Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Céline Deslarzes-Dubuis (C)

Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Alban Longchamp (A)

Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Martine Lambelet (M)

Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Charles K Ozaki (CK)

Department of Surgery and the Heart and Vascular Centre, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Jean-Marc Corpataux (JM)

Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Florent Allagnat (F)

Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland. Electronic address: florent.allagnat@chuv.ch.

Sébastien Déglise (S)

Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH